Q2 FY27 consolidated revenue INR 873.9 crore vs 730.6 crore year ago; PAT INR 193.9 vs 152.2 crore
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Smallcap 250 and 4.2 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For consolidated Q2 FY27 ended September 30, 2026, revenue from operations was INR 873.9 crore, up 19.6% from INR 730.6 crore a year earlier; PAT was INR 193.9 crore versus INR 152.2 crore. PAT rose 27.4%, while EBITDA margin rose 1.4 percentage points to 32.1%. Second interim dividend: INR 5 per share; record date November 11. Up to INR 49.5 crore approved for LPL Dubai, including up to INR 30 crore for Ghana's Sunshine Healthcare.
Higher PAT, wider EBITDA margin and the dividend may support the share price, while overseas funding may increase cash commitments.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.